Review of advances in CAR-T therapies in malignant hematology
Neda Amirmokhtari, Forat Lutfi
TL;DR
This review summarizes key developments in CAR-T therapies for blood cancers, including approvals, long-term data, and strategies to overcome resistance.
Contribution
The paper provides a comprehensive overview of recent advancements and resistance mechanisms in CAR-T therapies for hematologic malignancies.
Findings
Pivotal studies led to the approval of CAR-T therapies for hematologic malignancies.
Long-term and real-world data on CAR-T therapies are now available.
Mechanisms of resistance and potential novel therapies to overcome them are examined.
Abstract
There have been numerous advancements in immune cell effector therapies in the malignant hematology space. This review article explores the pivotal studies that led to the approval of chimeric antigen receptor T-cell (CAR-T) therapies for hematologic malignancies and highlights available associated long-term and real-world data. It also examines the mechanisms of resistance and potential novel therapies to overcome these mechanisms.
Genes, proteins, chemicals, diseases, species, mutations and cell lines named across the full text — each resolved to its canonical identifier and authoritative record.
Click any figure to enlarge with its caption.
Figure 1Peer Reviews
No public reviews on file for this paper yet. If you reviewed it on a platform where reviews are public (OpenReview, ICLR, NeurIPS, ICML), you can paste yours below so the community can read it here.
Videos
No videos yet. Explain this paper in a talk, walkthrough, or lecture? Add one.
Taxonomy
TopicsCAR-T cell therapy research · Cutaneous lymphoproliferative disorders research · Virus-based gene therapy research